Replies to post #155804 on Biotech Values

[genisi]

GILD’s ‘Quad Prime’ advances to phase-3

Although genisi disagrees), TAF is a crucially important compound for GILD insofar as it effectively extends the patent life of the Truvada franchise.

To be clear, the doubt I've raised is that TAF regimen (‘Quad Prime’) will differ from Viread regimen (Stribild) in safety/efficacy terms. No doubt it is a crucially important compound for GILD in its patent extension strategy. The question I've pointed to is important because if TAF proves to be superior to Viread, it would be easier for GILD to switch patients to the TAF regimen even before Viread goes generic and keep them after generic competition.